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Effect of thromboxane synthesis inhibition in a model of membranous
nephropathy. The effect of the thromboxane synthesis inhibitor UK
38485 on glomerular filtration rate (GFR) and proteinuria was evaluated
in a rat model of unilateral membranous nephropathy. Two and 24
hours following perfusion of kidneys with cationized human IgG and
i.v. administration of anti-human IgG-antiserum (in situ ICGN), gb-
merular thromboxane B2 (TxB2) formation was significantly higher (2
hr: 448 116 pg/mg protein/mm; 24 hr: 173 21 pg/mg protein/mm)
compared to control (C) kidneys (2 hr: 173 21 pg/mg protein/mi P <
0.005; 24 hr: 154 17 pg/mg protein/mm, P < 0.025). Two and seven
days after induction of ICON these differences were no longer present.
Pretreatment with the thromboxane synthesis inhibitor UK 38485
prevented the decrease in GFR, which occurred two hours after
induction of the glomerular disease (without UK: 161 31; with UK
325 21 t1/l00 g body wt/min). This UK 38485 effect on GFR was no
longer detectable at 24 hours, two days and seven days. Initiation of
glomerular immune injury was followed by significant proteinuria which
averaged 250 85 mg/24 hr at day two. UK 38485 treatment, which
reduced TxB2 formation in isolated glomeruli by 90% did not influence
proteinuria. These data demonstrate that induction of heterologous, in
situ immune complex glomerulonephritis stimulates glomerular throm-
boxane B2 formation, an effect which partially modulates the decrease
in GFR at two hours. Thromboxane, however, does not seem to play a
role in the mediation of proteinuria in this animal model.
Several animal models of immune and non-immune mediated
glomerular injury are associated with enhanced glomerular
thromboxane B2 production [1—8]. The implications of the role
of increased formation of glomerular TxA2 on the modulation of
glomerular hemodynamics and proteinuria are, however, con-
troversial.
Lianos, Andres and Dunn [1] first described glomerular TxB2
biosynthesis to be elevated in glomeruli of rats with anti-
glomerular basement membrane nephritis. The increment in
TxB2 formation was responsible for the decrease in glomerular
filtration rate in these animals, since a thromboxane synthesis
inhibitor maintained glomerular hemodynamics at the first three
hours after induction of nephrotoxic serum nephritis (NSN),
Studying the same animal model, Stork and Dunn [21 were
unable to demonstrate any effect of a thromboxane synthesis
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inhibitor and a receptor blocker on glomerular filtration rate
when rats were examined one and 14 days after induction of
disease. Rahman, Emancipator and Dunn [3] in another model
of immune complex glomerulonephritis could not demonstrate
any effect of increased TxA2 on glomerular hemodynamics.
In addition to the unsettled possible role of thromboxane in
the modulation of glomerular hemodynamics it is less clear if
thromboxane A2 is a mediator of proteinuria in glomerular
disease. Remuzzi et al [4] observed a significant reduction of
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proteinuria in a model of adriamycin nephropathy, without
effects on glomerular hemodynamics following thromboxane
synthesis inhibition. Similar results were obtained by Cybulsky
and coworkers [9] in a model of membranous nephropathy in
the isolated perfused rat kidney. In contrast to these observa-
tions other investigators, however, failed to demonstrate any
significant role of elevated thromboxane formation on the
mediation of proteinuria in immune-mediated glomerular injury
[2, 3, 81.
The possible role of thromboxane A2 on renal function in
glomerular disease is therefore undefined. In order to study
whether the difference of the role of thromboxane is dependent
on the stage of the disease we studied the role of thromboxane
synthesis inhibition on glomerular hemodynarnics and protein-
uria in the heterologous and autologous phase of a rat model of
membranous nephropathy. Our data suggest, that thromboxane
may modulate GFR in the heterologous phase of this disease.
The findings do not support a role of TxB2 in the development
of proteinuria, neither in the heterologous nor autologous phase
in this animal model of glomerular immune injury.
Methods
Materials
Radiochemicals were purchased from New England Nuclear
(Dreieich, FRG). Prostaglandins and TxB2 standards were from
Upjohn (Kalamazoo, Michigan, USA). Antisera for POE2 and
TxB2 were from Institut Pasteur (Paris, France). UK 38485 was
from Pfizer Pharmaceutical Company (Karlsruhe, FRG). BM
13505 was from Boehringer Mannheim (Mannheim, FRG).
mactin was from Byk-Gulden (Konstanz, FRG). Polyethylene
catheters were from Portex (Hythe, UK). FITC labeled antisera
were purchased from Nordic Immunochemicals (Tilburg, Ne-
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therland). Inulin was from Merck (Darmstadt, FRG). PAH was
from Sigma-chemicals (München, FRG).
Induction of nephritis
Nephritis was induced as previously described [10, 11] by
direct puncture of the left renal artery.
The left kidney was flushed with 0.5 ml PBS followed by an
injection of 100 ug cationized human IgG in a concentration of
16 mg/mI. Ischemia prevailed for four to six minutes. Antiserum
(10 mg in 0.5 ml PBS) was injected intravenously 15 minutes
after circulation was restored.
Preparation of cationized human IgG and anti-human IgG
antiserum
Cationization of human IgG was performed as described [101.
Antiserum to human IgG was prepared as follows: Rabbits were
immunized four times at monthly intervals with 500 jig human
IgG in Freunds-complete-adjuvant, and bled one week after the
last injection. The sera were complement inactivated by 30
minutes incubation in 56°C and were absorbed with rat eryth-
rocytes. The absorbed sera were precipitated twice with 50%
ammonium sulfate, dialyzed against PBS, sterile filtered
through a 0.45 jim membrane (Schleicher + Schüll, Dassel,
FRG). Aliquots were stored at —20°C until injection. The
anti-human IgG antiserum used in these experiments was from
a single pool.
Isolation and incubation of glomeruli
Kidneys were perfused in situ as outlined earlier [121. Cortex
and papillae were separated by scissor dissection. Glomeruli
were isolated by a sieving technique. The protein yield of the
glomerular isolation ranged from 300 to 500 jig per kidney. The
isolated glomeruli were transferred on a millipore filter and
superfused with Krebs-Ringer bicarbonate buffer under air
conditions. The incubation chambers were placed in a water
bath at 37°C. The incubation chambers and the length of the
tubing of all chambers were identical. About 4 ml of perfusate
was used in a closed system at a superfusion rate of 7 ml/min.
The details of this procedure have been described [13]. During
isolation procedure of glomeruli from animals treated with the
thromboxane synthesis inhibitor, UK 38485 was not present in
the isolation and superfusion solutions. At the end of each
superfusion period the perfusate was collected quantitatively on
ice and frozen at —20°C until analysis of PGE2 and TxB2. At the
end of each experiment the glomeruli were collected from the
filter. The glomeruli were then solubilized in 1 N NaOH for
analysis of glomerular protein content, which was determined
according to the method of Lowry et al [14].
Determination of prostaglandin E2 and thromboxane B2
Prostaglandin E2 and immunoreactive thromboxane B2 in the
urines and perfusates were determined by direct radioimmuno-
assay without prior extraction and chromatographic separation.
The radioimmunoassay procedures, the sensitivity and speci-
ficity of the antisera have been described in detail [13]. The
cross reactivities of the antisera are as follows: PGE2 antise-
rum, PGF, 0.06%, TxB2 0.01%; TxB2 antiserum, 6-keto-PGF
0.01%, arachidonic acid 0.0015%, PGE2 0.1%. The data of in
vitro PGE2 and TxB2 formation by glomeruli are presented in
picograms per mg glomerular protein content per minute incu-
bation time. Urinary prostanoids are expressed in picograms
per 24 hours and were determined in diluted urines.
Collection of 24 hour urine for protein and prostanoid
excretion
Animals were placed in metabolic cages for 24 hours with free
access to tap water and without food. Urine samples were
collected on meclofenamate (1 mg/ml). Samples were collected
and centrifuged at 1000 x g for 10 minutes. Protein content was
measured by the biuret method.
Inulin clearances
In in vivo experiments inulin clearances were determined in
rats from each group. The rats were anesthetized with mactin
(100 mg/kg body wt i.p.). A tracheostoma tube was inserted and
one jugular vein was cannulated with a PE-50 polyethylene
catheter. The right femoral artery was cannulated with a PE-50
polyethylene catheter, which was connected to a P-23-DC
Statham pressure transducer for continuous measurement of
arterial blood pressure. The left femoral artery was cannulated
with a PE-50 polyethylene catheter for collection of blood. A
PE-lO catheter was placed in each ureter for separate collection
of urine from each kidney. Each animal received 10 ml/kg of
0.9% saline solution over 10 minutes to replace fluid losses
during surgery. Then a bolus (3.7 mllkg body weight in 10 mm)
of a 1% inulin and PAH in 1.5% saline was given, followed by
an infusion rate of 0.9 ml/kg body wt/hr for a 60 minute control
period to reach constant urine flow. A 30-minute inulin clear-
ance period followed. Blood for determination of inulin concen-
tration was collected in the middle of the experimental period.
Inulin was determined according to the method of FrUh, Ka-
marcyk and KrUttgen [15].
Histological examination
At the end of the clearance periods (outlined in Experimental
design) kidney slices were obtained for light and electron
microscopy. Tissue was fixed in 4% buffered formalin. For light
microscopy, tissue was embedded in paraffin and stained by the
immunoperoxidase method for rat IgG, IgA, 1gM, Clq, C3 and
albumin. For electron microscopy tissue was fixed in methac-
rylate. Ultrathin sections were cut and examined by a Zeiss
GOT 902 microscope (Zeiss, Oberkochen, FRG).
Experimental design
Effect of in situ ICGN on glomerular prostanoid formation.
In situ ICGN was induced in the left kidneys as outlined above.
Animals were housed in metabolic cages every 48 hours for
urine collection. At 2 hours, 24 hours and two and seven days
animals were sacrificed and glomerular prostanoid formation
was evaluated. Glomeruli of the right kidneys served as control.
In additional rats, left renal arteries were perfused with
cationized human IgG without consecutive intravenous anti-
body administration. In other rats, left renal arteries were
perfused with 0.9% saline followed by intravenous antibody
injection. Glomerular prostanoid formation in these rats was
determined as described above.
Effect of intravenous UK 38485 on inulin clearance in control
and nephritic kidneys two hours after induction of glomerular
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injury. Animals were prepared for determination of inulin
clearance as outlined above. Nephritis was induced as outlined
above and Inulin clearance was measured two hours after
intravenous injection of the antibody. One group of rats re-
ceived 1.5 mg/kg body wt of the thromboxane synthesis inhib-
itor UK 38485 two hours prior to induction of ICGN. This was
followed by a constant infusion of UK 38485 (3.0 mg/kg body
wt/hr) until the end of the experiment. The kidneys were
removed for determination of glomerular prostanoid formation.
Effect of UK 38485 on GFR 24 hours and two days after
induction of disease. In situ ICON was induced as described
above. Two days prior to induction of glomerulonephritis rats
received the thromboxane synthesis inhibitor UK 38485 (50 mgI
kg body wt) every 12 hours orally until day two. The last dose
was given 16 hours prior to determination of glomerular pros-
tanoid formation. Control nephritic rats received UK 38485
solution (0.9% saline pH 8.4). Twenty-four hours and two days
after induction of glomerular disease clearances were per-
formed. At the end of the experiment kidneys were removed for
measurement of glomerular prostanoids.
Effect of intravenously administered UK 38485 and the
thromboxane receptor blocker (BM 13505) on GFR and RPF 24
hours after induction of disease. In additional experiments
nephritis was induced as described. Twenty-four hours after
antibody administration Inulin and PAH clearances were per-
formed in control nephritic animals and animals treated with the
thromboxane synthesis inhibitor UK 38485 and the thrombox-
ane receptor blocker BM 13505. UK 38485 was given as a bolus
injection of 1.5 mg/kg body wt two hours prior to clearance
studies, followed by a constant infusion of UK 38485 at an
infusion rate of 3.0 mg/kg body wt/hr. The thromboxane recep-
tor blocker was given in two separate intravenous bolus injec-
tions at 50 mg/kg body wt, 90 minutes and five minutes before
clearance studies started.
Effect of chronic thromboxane synthesis inhibition on pro-
teinuria and inulin clearance. Two days prior to induction of
glomerulonephritis, rats received the thromboxane synthesis
inhibitor UK 38485 (50 mg/kg body wt) every 12 hours orally
until day seven. The last dose was given 16 hours prior to
determination of glomerular prostanoid formation. Control ne-
phritic rats received UK 38485 solution (0.9% saline pH 8.4). In
both animal groups ICGN was induced. At days 2, 4 and 7
animals were placed in metabolic cages for a 24-hour urine
collection. At day 7 inulin clearances were measured for each
kidney in both animal groups. Kidneys were removed for
measurement of glomerular prostanoid production.
Statistical analysis
The data are presented as means SEM for unpaired data.
Statistical analysis was performed by Student's t-test; P values
less than 0.05 were considered significant.
Results
Effect of nephritis on glomerular prostanoid formation
Two and 24 hours following induction of nephritis, glomeru-
lar thromboxane B2 formation in the diseased kidneys was
significantly (P< 0.005) greater than in the contralateral control
kidneys (Fig. 1). These differences were no longer present two
and seven days following induction of the disease. Glomerular
Fig. 1. Glomerular iTxB2 formation in kidneys with in situ ICGN (D)
was significantly stimulated at 2 and 24 hours when compared to
normal control kidneys (El). At 2 days and 7 days these differences were
no longer present. Data are given as means SEM.
Table 1. UIomerular prostanoid formation in sham operated rats
Cationized antigen
intrarenaly not followed
by antibody (N = 5)
Saline intrarenaly
followed by antibody
intravenously (N = 5)
Normal Perfused
(right) (left)
kidney kidney
Normal Perfused
(right) (left)
kidney kidney
iTxB2
pg/rnglmin
PGE2
pg/rngirnin
259 43 295 34
326 66 325 28
146 21 176 40
250 40 283 45
prostaglandin E2 (PGE2) production was not affected at any
time of the experiments (control: 2 hr, 198 15;24hr, 135 12;
2 days, 174 18; 7 days, 207 11. ICGN: 2 hr, 202 12; 24 hr,
135 14; 2 days, 168 13; 7 days, 207 23 pg/mg protein/mm).
Cationized humtn IgG alone did not effect glomerular prosta-
noid formation in the perfused kidney, neither did anti-human
IgG antiserum alone (Table 1).
Inulin clearance two hours after induction of glomerular
injury
Two hours following antibody injection GFR in the diseased
left kidney was significantly lower when compared to the
healthy contralateral right kidney (Table 2). TxB2 formation in
the nephritic kidneys was about three times greater compared
to the glomerular formation of TxB2 in the normal contralateral
kidneys (Table 2). There was no significant difference in PGE2
formation between both kidneys (Table 2). The thromboxane
synthesis inhibitor UK 38485 prevented the increase in TxB2
formation following induction of immune renal injury in the left
kidneys and also significantly inhibited TxB2 production in
glomeruli of control rats (Table 2). UK 38485 did not influence
glomerular PGE2 formation in this protocol.
Glomerular filtration rate in the normal kidney of the UK
treated animals was not significantly different compared to the
animals which did not receive the thromboxane synthesis
inhibitor. GFR in nephritic kidneys which received UK 38485,
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PGE2 pg/mg/mm
iTxB2 pg/mg/mm
GFR.uJ/100 g body/wi mm
(1)—(2) NS
(3)—(4) NS
(5)—(6) P < 0.005
(7)—(8) P < 0.005
(5)—(7)P < 0.001
(6)—(8) P < 0.001
(9)—(l0) P < 0.05
(ll)—(12) NS
(l0)—(l2) P < 0.05
Table 3. Effect of oral UK 38485 on glomerular filtration rate
(l/minh100 g body wt) 24 hours and 2 days after induction of in situ
ICGN
ICGN-rat
Normal
(right)
kidney
s (N = 6)
Nephritic
(left)
kidney
ICGN-rats (N = 6)
treated with UK 38485
Normal Nephritic
(right) (left)
kidney kidney
24 hours 312 65 183 21 362 21 201 38
2 days 354 48 152 27 337 35 145 18
Table 4. Effect of intravenous UK 38485 and BM 13505 on GFR
(inulin clearance) (d/min/l00 g body wt) and RPF (PAH clearance)
(d/minI100 g body wt) 24 hours after induction of in situ ICGN
ICGN-rats (N = 5)
ICGN-rats (N = 6) treated
with UK 38485 + with BM
13505
Normal
(right)
kidney
Nephritic
(left)
kidney
Normal
(right)
kidney
Nephritic
(left)
kidney
GFR 310 70 123 25 350 25 116 20
PAH 3400 1200 396 70 3250 1300 525 110
clearance
however, was significantly higher compared to the animals
which did not receive the inhibitor (Table 2).
mu/in clearance 24 hours and two days after induction of
glomerular injury
Twenty-four hours and two days after induction of in situ
ICGN glomerular filtration rate was about 50% of control (Table
3). Thromboxane synthesis inhibition did not influence GFR at
these time points (Table 3).
mu/in and PAH clearances 24 hours after induction of
glomeru/ar injury: Effect of UK 38485 and BM 13505
Inulin and PAH clearances 24 hours after induction of gb-
merular immune injury were significantly lower when compared
to non-nephritic animals (Table 4).
Intravenous administration of a thromboxane synthesis inhib-
itor (UK 38485) and a thromboxane receptor blocker (BM
13505) did not increase inulin and PAH clearances in nephritic
rats (Table 4). Blood pressures were stable during the clearance
periods and were similar in both groups (systolic pressure 110
5 mm Hg, diastolic pressure 85 3 mm Hg).
Effect of chronic thromboxane synthesis inhibition on
glomerular filtration rate
GFR at day 7 in nephritic kidneys was significantly lower
compared to controls in both animal groups (UK treated and
untreated). GFR of normal kidneys in the UK treated versus the
untreated were not different (Table 5). Thus thromboxane
synthesis inhibition did not reverse GFR.
Effect of chronic thromboxane synthesis inhibition on
protein uria
Perfusion of the left renal artry with cationized human IgG
followed by intravenous antibody injection resulted in an onset
of proteinuria which averaged 250 85 mg/24 hours two days
after induction of nephritis (Fig. 2). Treatment with the throm-
boxane synthesis inhibitor UK 38485 two days prior to induc-
tion of unilateral glomerulonephritis did not prevent onset of
proteinuria (Fig. 2), even though urinary iTxB2 formation was
significantly inhibited by over 90%. Similarly, UK 38485 had
also no influence on the proteinuria in the autologous phase of
the disease (days 5 to 7) despite of significantly reduced iTxB2
production (Fig. 3).
Morphologic studies
Rats injected with cationized human IgG followed by an
intravenous application of anti-human IgG antibody developed
a severe proliferative glomerulonephritis in the left kidney (Fig.
5) when compared to control kidneys (Fig. 4). Imnlunohistobogy
revealed a granular pattern of rat IgG along the filtration barrier
when rats were studied at day 7 (Fig. 5). Electron microscopy
demonstrated subepithelial imifiune deposits (Fig. 5). UK 38485
treatment did not influence immunohistology and subepithelial
immune deposit formation (Fig. 6).
Discussion
Induction of unilateral in situ ICGN resulted in a significant
increase of glomerular TxB2 formation at two and 24 hours.
TxB2 biosynthesis was increased about threefold at two hours
and almost doubled 24 hours following induction of glomerular
injury. The increased production of TxB2 seen at two and 24
hours was no longer present two and seven days after induction
of immune complex injury.
Table 2. Effect of i.v. UK 38485 on GFR and glomerular PGE2 and TxB2 formation on control and nephritic kidneys two hours after
induction of in situ ICGN
ICGN-rats
Normal (right)
(N = 8)
Nephritic
ICNG-rats treated with UK 38485 (N = 8)
Normal (right) Nephritic
kidney (left) kidney kidney (left) kidney
(1) 202 35 (2) 210 17 (3) 235 28 (4) 217 16
(5) 156 27 (6) 432 68 (7) 11 3 (8) 29 2
(9) 307 87 (10) 161 31 (Il) 398 16 (12) 325 21
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(l)—(2) P < 0.05
(3)—(4) P < 0.001
(1)—(3) NS
(2)—(4) NS
Table 5. Effect on chronic treatment with UK 38485 (seven days) on GFR in normal and nephritic kidneys
(5)—(6) NS
(7)—(8) NS
(10)—(12) NS
Fig. 2. Proteinuria in rats with in Situ ICGN () was not affected by
treatment with the thromboxane synthesis inhibitor UK 38485 (E).
Data are given as means SEM.
Glomerular disease was initiated by selective perfusion of the
left kidneys with cationized human IgG. Kidney perfusion was
followed by the intravenous administration of rabbit anti-human
IgG antibody. This results in an immune glomerular injury
which is similar to the morphology observed by Vogt et al in the
original description of this model of glomerular injury [10].
Mediation of disease in this model depends on complement
activation, polymorphonuclear leukocytes and monocytes [16].
The increase in glomerular TxB2 formation in this animal
model confirms earlier observations in various other models of
immune-mediated glomerular injury [1—81.
It is unlikely that glomerular endothelial, epithelial and
mesangial cells [17, 18] are the only source of stimulated
thromboxane formation, since the mediation of this disease
partially depends on blood-derived inflammatory cells. Partic-
ularly monocytes are of significance in the mediation of pro-
teinuria [16]. Since macrophages are a major source of prosta-
noid biosynthesis [19], these cells might participate in the
stimulated thromboxane formation [6] found at two and 24
hours.
TxB2 in isolated glomeruli might also be synthesized by
intrinsic glornerular cells due to an activation of the comple-
Fig. 3. The thromboxane synthesis inhibitor UK 38485 () signfi-
cantly reduced urinary TxB2 excretion in nephritic rats when
compared with UK 38485-untreated animals (0). Data are
given as means SEM.
ment system [8, 9]. Lovett et al [20] and Hansch et al [21] found
that the membrane attack complex increases prostanoid forma-
tion in glomerular mesangial and epithelial cells in culture. In
addition we have demonstrated that activation of the comple-
ment system in vivo accounts at least in part for the elevated
prostanoid production in the animal model of passive Heymann
nephritis [8]. Terminal complement components seem to also
play a significant role in the mediation of proteinuria in the
studied model [22]. The activation of the complement system
might therefore be a mediator of increased prostanoid produc-
tion in isolated glomeruli.
GFR in nephritic kidneys fell significantly compared to
normal controls. GFR was reduced from two hours to seven
days (Table 2). The fall in GFR at two hours following induction
of disease was prevented by pretreatment with UK 38485.
When animals were studied at 24 hours and seven days UK
38485 did not reverse the fall in GFR. This was surprising since
at 24 hours glomerular TxB2 biosynthesis was still elevated. To
validate this negative result at 24 hours, rats in addition to UK
ICGN-rats (N = 7) ICGN-rats treated with UK 38485 (N = 8)
Normal (right) NephriticNormal (right) Nephritic
kidney (left) kidney kidney (left) kidney
GFR d/min/1OO g body wt (1) 321 89 (2) 136 26 (3) 309 46 (4) 76 19
Glom. iTxB2 pg/mg/mm (5) 152 127 (6) 163 68 (7) 47 17 (8) 51 14
Glom. PGE2pg/mg/mmn (9) 202 35 (10) 210 15 (11) 235 45 (12) 227 11
15,000
- 10,000 II
5,000 P<0.001 P<0.001 P<0001
2 4 7
TIme, days
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Fig. 4. Non-nephritic, control kidney. A. Immunoperoxidase reaction on paraffin section was negative for rat LgG (x 570). B. Electron micrograph
demonstrates normal filtration barrier (x 12000).
Fig. 5. Nephritic kidney seven days after induction of disease. A. Immunoperoxidase staining demonstrates a granular pattern for rat IgG along
the capillary wall (x 570). B. Electron microscopy demonstrates subepithelial immune deposits (x 16000).
38485 also received the thromboxane receptor blocker BM
13505 intravenously. This combined drug treatment, however,
did not prevent the fall in GFR in nephritic kidneys at 24 hours.
This negative finding on the role of TxB2 in GFR is similar to
observations by Rahman, Emancipator and Dunn [31. These
investigators failed to demonstrate any effect of elevated TxB2
on glomerular hemodynamics in another model of membranous
nephropathy.
A protective effect of a thromboxane synthesis inhibitor on
the reduction of GFR in the early heterologous phase of
glomerular immune injury has been demonstrated by Lianos,
Andres and Dunn [1] in a model of nephrotoxic serum nephritis
(NSN). In the animal model of NSN, however, in addition to
increased glomerular TxB2 formation, Lianos et al [1] and Stork
and Dunn [21 found an increased production of vasodilatory
PGE2 in isolated glomeruli. Based on their functional studies
Stork and Dunn [2] concluded that PGE2 was the predominant
prostanoid in this model. In our study, however, the balance
between PGE2 and TxB2 is in favor of TxB2 at least at two and
24 hours. The ratio of TxB2/PGE2 is maximal at two hours after
induction of in situ ICGN. This is the only time when UK 38485
prevented the decrease in GFR. It is therefore possible that
thromboxane is hemodynamically effective only when TxB2 is
inappropriately stimulated compared to the vasodilatory pros-
tanoids. This suggestion is supported by data derived from
other animal models where the onset of renal disease results in
a remarkable imbalance between vasoconstrictor and vasodila-
tory prostanoids in favor of TxB2 [23—261,
Induction of in situ ICGN is followed by proteinuria within 24
hours after induction of disease. Proteinuria averaged from 200
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Fig. 6. Nephritic kidney seven days after induction of disease treated with UK 38485. A. Immunoperoxidase staining for rat IgG was not different
from untreated, control nephritic kidneys (x 570). B. Subepithelial immune deposits were unaffected by UK 38485 as demonstrated by electron
microscopy (x 16000).
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